sla buy more bpo, page-8

In addition to the right to appoint two members of the BioProspect Board, Solagran will
receive 22.5 million shares and 22.5m options ($0.05, 2010) in BioProspect, together with a
further 22.5 million shares and 22.5m options ($0.05,2010) upon BioProspect completing its
funding obligations and proceeding to full commercialisation.
BioProspect will retain exclusive rights to those existing Bioeffectives that have application in
the animal health, animal nutrition and agriculture markets – subject to realisation of certain
revenue targets by December 2010. If exclusivity is maintained, Solagran will receive a
further $2.5 million worth of BioProspect shares together with free attaching options at a
three month Volume Weighted Average Price (VWAP) as at 31 December 2007.
BioProspect will acquire 2.5 million unlisted options in Solagran, and exercise these options
on or before 31 August 2007, injecting $500,000 into Solagran.